Breast Cancer
Conditions
Interventions
None listed
Sponsors
Saitama Breast Cancer Clinical Study Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Advanced breast cancer patients with moderate to severe pain
Exclusion criteria
Exclusion criteria: Oxnorm Contraindications 1)Severe respiratory depression, severe COPD 2)During acute attack of bronchial asthma 3)Secondary cardiac failure of chronic pulmonary diseases 4)During convulsive state 5)Paralytic ileus 6)Hypersensitivity to a group of opium alkaloids 7)Hemorrhagic colitis 8)Bacterial diarrhea OneDuro Patch Contraindication 1)hypersensitivity to any of the ingredients of the product Careful Administration 2)Respiratory dysfunctions such as chronic lung diseases 3)Asthma 4)Severe bradyarrhythmia 5)Severe hepatic or renal dysfunction 6)Organic brain disorders such as intracranial hypertension, disturbed consciousness, coma or brain cancer 7)Skin diseases such as atopic dermatitis ieczema on adhesive site 8)40dgree or more fever 9)History of drug dependence 10)Pregnancy, nursing women 11)Within next 2 days before using Fentanyl patch, antagonists of opioid receptor such as Pentazocine or Buprenorphine etc. are administered or planned to administer 12)below the age of 20 13)Attending doctors judgement
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient satisfaction at day 14 and day 28 | — |
Secondary
| Measure | Time frame |
|---|---|
| Physician satisfaction at day 28 Pain degree at day 14 and day 28 4-level evaluation of Nausea, Vommiting, constipation, daytime drowsiness at day 14 and day 28 | — |
Countries
Japan
Contacts
Public ContactToshihiro Kai
Shintoshin Ladies' Mammoclinic Surgery
Outcome results
None listed